



COPY RECEIVED
SEP 25 2003
TECH CENTER 1600/2900

5218.39B/KDS:vp
January 21, 2002

Commissioner for Patents
Washington, DC 20231

Sir: Kindly acknowledge receipt of the accompanying by placing your
receiving date stamp hereon and mailing:
Re: Anagnostou, et al.; S/N 09/525,797; Filed 3/15/00

IDS (W/21 REF.)



Respectfully,
MYERS BIGEL SIBLEY & SAJOVEC, P.A.
Attorneys for Applicant

Attorney's Docket No. 5218.39

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Anagnostou, et al.
Serial No. 09/525,797
Filed: 15 March 2000
For: METHOD OF TREATING ENDOTHELIAL INJURY

January 21, 2002


Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a list of documents on form PTO-1449. Items 1-21 listed on the PTO-1449 were cited in parent application Serial No. 08/712,358, filed 11 September 1996. Since the benefit of this application is claimed under 35 U.S.C. §120, no copies need to be furnished in accordance with 37 C.F.R. §1.98(d); however, copies will be furnished on request. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. §1.97 and Section 609 of the MPEP.

Respectfully submitted,


Kenneth D. Sibley
Registration No. 31,665




20792

PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, DC 20231, on January 21, 2002.



Vickie Diane Prior

Date of Signature: January 21, 2002

RECEIVED
SEP 25 2003
TECH CENTER 1600/2900

Attorney's Docket No. 5218-39B

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Anagnostou et al.

Serial No.: 09/525,797

Filed: March 15, 2000

For: *METHOD OF TREATING ENDOTHELIAL INJURY*

Confirmation No. 9917

Group Art Unit: 1642

Examiner: Susan Ungar

September 16, 2003

Mail Stop RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a list of documents on Form PTO-1449, along with a copy of each listed document. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP.

This Supplemental Information Disclosure Statement and Form PTO-1449 are submitted in accordance with 37 C.F.R. § 1.97(b)(4), before the mailing of a first Office Action after the filing of a Request for Continued Examination. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,



Shawna Cannon Lemon

Registration No. 53,888

Myers Bigel Sibley & Sajovec, P.A.

P. O. Box 37428, Raleigh, NC 27627

Telephone: (919) 854-1400

Facsimile: (919) 854-1401

Customer No. 20792

Certificate of Mailing under 37 CFR § 1.8


I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 16, 2003.



Susan E. Freedman

Date of Signature: September 16, 2003

RECEIVED
SEP 25 2003
TECH CENTER 1600/2900



Substitute form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<div style="border: 1px solid black; border-radius: 50%; padding: 10px; display: inline-block; text-align: center;"> O I P E SEP 2 2 2003 TRADEMARK OFFICE </div>				Complete if Known Application Number: 09/525,797 Filing Date: 15 March 2000 First Named Inventor: Athanasios A. Anagnostou Group Art Unit: 1642 Examiner Name: S. Ungar Attorney Docket Number: 5218.39B			
Sheet	1	of	1								
U.S. PATENT DOCUMENTS											
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear					
		Number	Kind Code (if known)								
	1	4,745,099		Akamatsu et al.	5/17/88						
	2	5,635,160		Stutts, et al.	3/6/97						
FOREIGN PATENT DOCUMENTS											
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		T		
		Office	Number	Kind Code (if known)							
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS											
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published									T
	3	Anagnostou et al., <i>Erythropoietin Has a Mitogenic and Positive Chemotactic Effect on Endothelial Cells</i> , Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 5978-5982 (1990)									
	4	Cao, et al., <i>gro-α, a C-X-C-Chemokine Is an Angiogenesis Inhibitor That Suppresses the Growth of Lewis Lung Carcinoma in Mice</i> , J. Exp. Med., Vol. 182, 2069 (1995)									
	5	Carlini et al., <i>Effect of Recombinant Human Erythropoietin (rHuEPO) on Apoptosis in Endothelial Cells</i> , J. Amer. Society Nephrology, Vol. 7, No. 9, pp. 1559; Abstract A1548 (1996)									
	6	Carlini, et al., <i>Recombinant Human Erythropoietin Stimulates Angiogenesis</i> , Kidney International, Vol. 47, pp. 740-745 (1995)									
	7	Cazzola, M., <i>Erythropoietin: biology and clinical applications</i> , Trends in Experimental and Clinical Medicine, Vol. 3, pp. 344-361 (1993)									
	8	Hand, et al., <i>Erythropoietin Enhances Vascular Responsiveness to Norepinephrine in Renal Failure</i> , Kidney International, Vol. 48, pp. 806-813 (1995)									
	9	International Search Report for PCT/US97/15966									
	10	Kumar, et al, Basic Pathology, W. B. Saunders Company, Philadelphia, pg. 194 (1992)									
	11	Kuriyama et al., <i>Evidence for Amelioration of Endothelial Cell Dysfunction by Erythropoietin Therapy in Predialysis Patients</i> , Am. J. Hyperten, Vol. 9, No. 5, pp. 426-431 (1996)									
	12	Kuwata, et al., <i>Treatment of Metastatic Liver Tumors by Intermittent Repetitive Injection of an Angiogenesis Inhibitor Using an Implantable Port System in a Rabbit Model</i> , Kobe J. Med. Sci., Vol. 43, No. 2, pp. 83-98 (1997)									
	13	Livnah, et al., <i>Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 Å</i> , Science, Vol. 273, pp. 464-471 (1996)									
	14	Maier, et al., <i>In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-470) and the anti-endoglin antibody TEC-11</i> , Anti-Cancer Drugs, Vol. 8, pp. 238 (1997)									
	15	Markham, et al., <i>Epoetin Alfa, A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Nonrenal Applications</i> , Drugs, Vol. 49, No. 2, pp. 232-254 (1995)									
	16	Nagai, et al., <i>Effects of rHuEpo on Cellular Proliferation and Endothelin-1 Production in Cultured Endothelial Cells</i> , Nephrol Dial Transplant, Vol. 10, pp. 1814-1819 (1995)									
	17	Pluda, J.M., <i>Tumor-Associated Angiogenesis: Mechanisms, Clinical Implications, and Therapeutic Strategies</i> , Seminars in Oncology, Vol. 24, pp. 203 (1997)									
	18	Takano, et al., <i>A Diaminoanthraquinone Inhibitor of Angiogenesis</i> , J. Pharmacol. Exp. Ther., Vol. 271, pp. 1027 (1994)									
	19	Wrighton, et al., <i>Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin</i> , Science, Vol. 273, pp. 458-463 (1996)									
	20	Yamaji et al., <i>Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA</i> , European J. Biochem., Vol. 239, pp. 494-500 (1996)									
	21	Yamaji, et al., <i>Brain Capillary Endothelial Cells Express Two Forms of Erythropoietin Receptor mRNA</i> , Eur. J. Biochem., Vol. 239, pp. 494 (1996)									

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449/PTO			Compl te if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/525,797	
			Filing Date	03/15/2000	
			First Named Inventor	Athanasius A. Anagnostou	
			Group Art Unit	1642	
			Examiner Name	Susan Ungar	
Sheet	1	of	1	Attorney Docket Number	5218-39B

U.S. PATENTS AND PATENT PUBLICATIONS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	1	JP	02 096535	A	Chugai Pharm Co Ltd	04/09/1990	Abstract	

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	2	Communication with Supplementary European Search Report, EP 97 94 0974, July 15, 2002	
	3	Bukowski et al., <i>Phase IV evaluation of clinical outcomes of PROCRIT (Epoetin alfa) in anemic cancer patients receiving chemotherapy</i> , Blood, Journal of the American Society of Hematology, Vol. 84, No. 10, Supp. 1, December 1994, p. 129A	
	4	Taylor et al., <i>Effect of nifedipine on changes in fibrinogen and von Willebrand factor in haemodialysis patients treated with recombinant human erythropoietin</i> , Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis, Vol. 6, No. 2, April 1995, pp. 100-104	
	5	Taylor et al., <i>Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients</i> , Kidney International, Vol. 44, No. 1, July 1993, pp. 182-190	
	6	Reinhart, <i>Shear-dependence of endothelial functions</i> , Experientia, Vol. 50, No. 2, February 15, 1994, pp. 87-93	
	7	U.S. Patent Application Serial No. 09/525,808, filed March 15, 2000	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.